These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37537301)

  • 21. NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity.
    Nielsen MM; Dyring-Andersen B; Schmidt JD; Witherden D; Lovato P; Woetmann A; Ødum N; Poulsen SS; Havran WL; Geisler C; Bonefeld CM
    J Invest Dermatol; 2015 May; 135(5):1311-1319. PubMed ID: 25634359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NKG2D Enhances Double-Negative T Cell Regulation of B Cells.
    Hu SH; Zhang LH; Gao J; Guo JH; Xun XD; Xiang X; Cheng Q; Li Z; Zhu JY
    Front Immunol; 2021; 12():650788. PubMed ID: 34220808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
    Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR
    Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D).
    Wang J; Nakafuku KM; Ziff J; Gelin CF; Gholami H; Thompson AA; Karpowich NK; Limon L; Coate HR; Damm-Ganamet KL; Shih AY; Grant JC; Côte M; Mak PA; Pascual HA; Rives ML; Edwards JP; Venable JD; Venkatesan H; Shi Z; Allen SJ; Sharma S; Kung PP; Shireman BT
    Bioorg Med Chem Lett; 2023 Nov; 96():129492. PubMed ID: 37778428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
    Zhu M; Huang Y; Bender ME; Girard L; Kollipara R; Eglenen-Polat B; Naito Y; Savage TK; Huffman KE; Koyama S; Kumanogoh A; Minna JD; Johnson JE; Akbay EA
    Cancer Res; 2021 Apr; 81(7):1813-1826. PubMed ID: 33495232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts.
    Phillips LK; Gould EA; Babu H; Krams SM; Palmer TD; Martinez OM
    Stem Cells; 2013 Sep; 31(9):1829-39. PubMed ID: 23733329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
    Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
    J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
    Maccalli C; Scaramuzza S; Parmiani G
    Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology.
    Secchiari F; Nuñez SY; Sierra JM; Ziblat A; Regge MV; Raffo Iraolagoitia XL; Rovegno A; Ameri C; Secin FP; Richards N; Ríos Pita H; Vitagliano G; Rico L; Mieggi M; Frascheri F; Bonanno N; Blas L; Trotta A; Friedrich AD; Fuertes MB; Domaica CI; Zwirner NW
    Oncoimmunology; 2022; 11(1):2104991. PubMed ID: 35936986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.
    Cerwenka A; Lanier LL
    Tissue Antigens; 2003 May; 61(5):335-43. PubMed ID: 12753652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.
    Kucuk B; Yilmaz E; Cacan E
    Mol Biol Rep; 2021 May; 48(5):3999-4008. PubMed ID: 34009568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
    Basher F; Jeng EK; Wong H; Wu J
    Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism.
    Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101029. PubMed ID: 34486239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
    Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
    Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
    Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenetics of the NKG2D ligand gene family.
    Kasahara M; Yoshida S
    Immunogenetics; 2012 Dec; 64(12):855-67. PubMed ID: 22843249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.